Gülhan, Pınar YıldızElverişli, Mehmet Fatih2021-12-012021-12-0120202636-76882636-7688https://doi.org/10.5455/annalsmedres.2020.01.063https://app.trdizin.gov.tr/makale/TXpneU9EWTBOQT09https://hdl.handle.net/20.500.12684/9711Aim: This study examined the effects of monocyte/high-density lipoprotein cholesterol (HDL-C) ratio (MHR) and other inflammatorymarkers in patients with sarcoidosis not receiving treatment. To our knowledge, this is the first study on the relationship betweensarcoidosis and MHR.Material and Methods: This study included 53 patients with sarcoidosis who were followed at a single, outpatient tertiary-carecentre. Data on patient demographics (age and gender), disease characteristics (duration of disease, radiographic stage, treatments);pulmonary function tests (% predicted values for forced vital capacity [FVC], forced expiratory volume at 1 second [FEV1], diffusingcapacity of the lungs for carbon monoxide [DLCO], alveolar volume [VA], forced expiratory flow [25–75% and at 50%; FEF] [FEF25-75]),blood biochemistry and hemogram findings were retrieved from hospital records.Results: Mean ± SD patient age was 51.13 ±1 1.94 years. Of the 53 patients, 42 were female and 11 were male. When compared withMHR ratio and pulmonary function test parameters, there was a negative correlation with FEV1% (P = 0.043, r = ?0.279) and DLCO% (P= 0.009, r = –0.360). There was no significant correlation between FVC, FEV25-75 or VA. No significant correlation was found betweenblood calcium, urinary calcium, SACE (serum angiotensin converting enzyme) values and MHO ratio.Conclusions: Large-scale prospective studies are needed to determine if the use of MHR as an indicator of inflammation andactivation would be helpful in the diagnosis and monitoring of patients with sarcoidosis.en10.5455/annalsmedres.2020.01.063info:eu-repo/semantics/openAccess[No Keywords]Article27617281732